23rd Annual International Congress on Hematologic Malignancies 2019: Focus on Leukemias, Lymphomas and Myeloma
The annual International Congress on Hematologic Malignancies is dedicated to providing clinicians access to emerging data in treating hematologic malignancies. Providing practical tools to optimize therapy and personalize care.
Our Chief Medical Officer Dr. Maher Albitar will be presenting Beyond Genomics: Integrating Molecular Medicine in Our Practice on Friday March 1st, 8:40am.
Few words about the Congress
Now in its 23rd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma provides practitioners who manage hematologic malignancies the practical tools to translate emerging data into the best therapy for patients with these tumors, personalize care based upon patient and tumor characteristics, and apply novel management strategies to their practices to improve outcomes for their patients.
Back by popular demand! This 3.5-day meeting will be held from Thursday through mid-afternoon Sunday. As always, agenda topics will focus on methods to apply state-of-the-art strategies to your clinical practice settings. This engaging and highly interactive meeting will provide ample opportunity to interact with internationally renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend methods to place this information in its proper clinical context so it can be applied to the real-world care scenarios you encounter. In doing so, a focus will be placed on how to proactively mitigate and manage treatment-related toxicities associated with new treatment strategies.
The well-known and highly interactive Medical Crossfire® discussion panels interspersed throughout the meeting will allow attendees to explore some of the most challenging clinical situations in the management of hematologic malignancies, many of which have multiple potential approaches to care.
This dynamic Congress will challenge participants to apply new information they have learned, reflect on new practices they can bring back to their clinics to share with their peers, and ultimately improve patient outcomes in their practice settings.
Acknowledgement of Commercial Support
This activity is supported by educational grants from AbbVie Inc., Acerta Pharma – A member of the AstraZeneca Group, Adaptive Biotechnologies, Celgene Corporation, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Jazz Pharmaceuticals, Inc., NewLink Genetics, Novartis Pharmaceuticals Corporation, Rigel Pharmaceuticals, Inc., Seattle Genetics, Inc., and Takeda Oncology.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
Hot Topics for 2019:
- The expanding role of new immunologic approaches, including CAR T cells and checkpoint inhibitors, in hematologic malignancies
- The emergence of molecular-based therapies and new cytotoxic formulations in patients with acute leukemias
- Effective utilization of the increasing therapeutic armamentarium in multiple myeloma
- New clinical considerations for frontline and subsequent strategies for Hodgkin and non-Hodgkin lymphomas
- Patient, disease, and drug characteristics will inform sequencing decisions in patients with chronic lymphocytic leukemia
- New approaches for treatment and duration of therapy among patients with myeloproliferative neoplasms
The Congress will take part in:
Thursday, February 28, 2019 – Sunday, March 3, 2019
Eden Roc Miami
4525 Collins Avenue
Miami Beach, FL, 33140